ScholarLens Back to search
2018•Annals of the Rheumatic DiseasesOpen access

THU0211 Six months after treatment discontinuation tnf is still in complex with adalimumab

Merel J l'Ami, Lea C. Berkhout, Michael Twahier Nurmohamed, Ronald van Vollenhoven, Maarten Boers, J. Ruwaard, Femke Hooijberg, Theo T. Rispens, Gertjan Wolbink

Open full text 2 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Adalimumab, Medicine, Discontinuation, Tumor necrosis factor alpha, TNF inhibitor, Antirheumatic Agents, Etanercept, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
THU0211 Six months after treatment discontinuation tnf is still in complex with adalimumab — Research Paper | ScholarLens